Premier Alternatives

Delix Therapeutics

Drug Discovery · Bedford, MA · Founded 2019 · Privately Held (backing)

Developer of neuroscience therapeutics designed to address mental health and central nervous system conditions. Delix Therapeutics is based in Bedford, MA and was founded in 2019. It was valued at $156 million at a grant in Jun 2024, the last priced event on record. It has raised $109 million across 1 recorded round; the latest was a $70 million Series A in Sep 2021.

PMV mark · valuation
$156.2M
Oct 2026
Priced at
a grant
Jun 2024
Total raised
$108.5M
Last round
Early Stage VC (Series A)
Sep 2021

Delix Therapeutics key facts

as of Oct 2026
  • Developer of neuroscience therapeutics designed to address mental health and central nervous system conditions.
  • Delix Therapeutics is valued at approximately $156.2M as of Oct 2026, set at a grant, Jun 2024; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $108.5M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($70.0M) in Sep 2021.
  • Notable investors include Gaingels, RA Capital Management, Calm Ventures, United States Department of War, Dolby Family Ventures — 40 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$156.2M

Valued at $156.2M at a grant, Jun 2024. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Delix Therapeutics with a free account
  • ·The complete investor list: 40 names
  • ·Watch Delix Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Delix Therapeutics funding rounds

1 rounds
Sep 2021Early Stage VC (Series A)$70.0M▮
Full funding history →

Delix Therapeutics valuation

Delix Therapeutics was valued at $156 million at a grant in Jun 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Delix Therapeutics raised?

Delix Therapeutics has raised $109 million in total; 1 of its rounds is on record. The largest on record was a $70 million Series A in Sep 2021.

Delix Therapeutics investors

40 investors are on record for Delix Therapeutics, including Gaingels, RA Capital Management, Calm Ventures and United States Department of War. By type, the record holds 6 venture capital firms, 3 family offices and 1 asset manager. The Series A in Sep 2021 drew 17 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Gordian Biotechnology ($170 million), Claris Bio ($163 million) and Sparrow Pharmaceuticals ($139 million).

About Delix Therapeutics

Developer of neuroscience therapeutics designed to address mental health and central nervous system conditions. The company's platform discovers and develops non-hallucinogenic small molecules that induce selective neuroplasticity for therapeutic effects, enabling the treatment of depression, post-traumatic stress disorder, substance use disorders, and related neuropsychiatric and neurodegenerative diseases.

Industry
Drug Discovery
Sector
Healthcare
HQ
Bedford, MA, United States
Founded
2019
Employees
25
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.